Jeanette Reinshagen

Optimization and evaluation of complementary degrader discovery assays for application in screening

The paper optimizes and evaluates two cell-based assays for degrader discovery, finding that the signal rescue assay reliably identifies active degraders and filters out non-specific compounds.

Interdisciplinary Study on Drug-Induced-Phospholipidosis of Repurposing Libraries through Machine Learning and Experimental Evaluation in Different Cell Lines

The paper develops a machine learning model to predict drug-induced phospholipidosis using a large dataset of repurposed drugs tested across multiple cell lines.

From Library to Landscape: Integrative Annotation Workflows for Compound Libraries in Drug Repurposing

The paper develops two annotation pipelines and dashboards to integrate chemical and bioactivity data for drug repurposing, validated on a compound library with over 5000 compounds.

Resolving the pharmacological redox-sensitivity of SARS-CoV-2 PLpro in drug repurposing screening enabled identification of the competitive GRL-0617 binding site inhibitor CPI-169

The paper identifies CPI-169 as a competitive inhibitor of SARS-CoV-2 PLpro that targets the same binding site as GRL-0617, through a drug repurposing screening approach that accounts for redox-sensitivity.

The novel coronary artery disease risk factor ADAMTS-7 modulates atherosclerotic plaque formation by degradation of TIMP-1

This study identifies ADAMTS-7 as a risk factor for atherosclerosis by degrading TIMP-1, reducing its inhibition of MMP-9 and promoting collagen degradation.

Identification of inhibitors of SARS-CoV-2 3CL-Pro enzymatic activity using a small molecule in-vitro repurposing screen

The paper identifies 62 new inhibitors of SARS-CoV-2 3CL-Pro through a compound repurposing screen and validates their activity using X-ray crystallography.

The COVID-19 PHARMACOME: A method for the rational selection of drug repurposing candidates from multimodal knowledge harmonization

The paper presents a drug-target-mechanism graph to identify synergistic drug combinations for SARS-CoV-2 treatment, validated through experimental testing.